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Objective. To evaluate the antitumor effect of cyclodextrin-curcumin complex (CDC) on human and rat urothelial carcinoma cells
in vitro and to evaluate the effect of intravesical instillations of CDC, BCG, and the combination in vivo in the AY-F344 orthotopic
bladder cancer rat model. Curcumin has anticarcinogenic activity on urothelial carcinoma and is therefore under investigation for
the treatment of non-muscle invasive bladder cancer. Curcumin and BCG share immunomodulating pathways against urothelial
carcinoma. Methods. Curcumin was complexed with cyclodextrin to improve solubility. Four human urothelial carcinoma cell
lines and the AY-27 rat cell line were exposed to various concentrations of CDC in vitro. For the in vivo experiment, the AY-27
orthotopic bladder cancer F344 rat model was used. Rats were treated with consecutive intravesical instillations of CDC, BCG,
the combination of CDC+BCG, or NaCl as control. Results. CDC showed a dose-dependent antiproliferative effect on all human
urothelial carcinoma cell lines tested and the rat AY-27 urothelial carcinoma cell line. Moreover, intravesical treatment with CDC
andCDC+BCG results in a lower percentage of tumors (60% and 68%, respectively) compared to BCG (75%) or control (85%).This
difference with placebo was not statistically significant (p=0.078 and 0.199, respectively). However, tumors present in the placebo
and BCG-treated rats were generally of higher stage. Conclusions. Cyclodextrin-curcumin complex showed an antiproliferative
effect on human and rat urothelial carcinoma cell lines in vitro. In the aggressive orthotopic bladder cancer rat model, we observed
a promising effect of CDC treatment and CDC in combination with BCG.
1. Introduction
New treatment options for patients with non-muscle inva-
sive bladder cancer (NMIBC) are urgently needed. Despite
transurethral resection and adjuvant treatment with intraves-
ical instillations, these bladder tumors recur in around one-
third to two-thirds of patients, depending on risk category
[1, 2]. Based on tumor characteristics and other parameters,
the NMIBC-patient is classified in a risk category and treated
adjuvantly: in general, intermediate-risk patients receive
intravesical chemotherapy whereas high-risk patients are
treated with intravesical Bacillus Calmette Gue´rin (BCG)
[2]. Even after BCG treatment for 1-3 years, the 5-yr risk of
recurrence is 41.3% [1].
Besides suboptimal oncological results, there are also
considerable side effects ranging from mild urogenital com-
plaints to severe systemic side effects. Additionally, due
to recent BCG shortage, future alternatives for adjuvant
treatment are more than welcome.
Curcumin is a component of dried turmeric powder, a
food spice derived from the plant Curcuma Longa. Curcumin
is a nontoxic agent, with anti-inflammatory, antioxidant, and
anticarcinogenic activity [3, 4], including apoptotic effects on
urothelial carcinoma (UC) in vitro [5, 6] and in vivo [7–10].
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The molecular mechanisms underlying the antitumor effect
have not been fully unraveled. Treatment with curcumin
leads to downregulation of cell-signaling pathways respon-
sible for proliferation, invasion, and angiogenesis [7, 11–13]
by suppressing activating transcription factors like NF-𝜅B
[7, 14].
Curcumin also enhances pathways mediated by tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL),
an apoptosis-inducing cytokine that targets human cancer
cells specifically [15]. Interestingly, induction and expression
of TRIAL by polymorphonuclear neutrophils are a key step
in the therapeutic effect of BCG treatment for NMIBC [13]:
the relative specificity of TRAIL to tumor cells may explain
the selectivity of the BCG-induced immune response against
bladder cancer [13]. Curcumin may potentiate the efficacy
of BCG, since it upregulates the expression of DR-5, one
of the main receptors for TRAIL [7, 15]. Sharing pathways
responsible for tumor selective apoptosis, curcumin, and
BCG may have a synergistic antiproliferative effect on UC
[7].
Because the aqueous solubility of curcumin is low, the
bioavailability after systemic or topical administration is
modest [16]. Complexing the curcumin to cyclodextrin
improves the aqueous solubility [17], thereby increasing its
cellular uptake and efficacy in vitro and in vivo [18, 19]. Using
a pH shift method, we prepared a concentrated aqueous
solution of cyclodextrin-curcumin complex (CDC) which
is stable even in the presence of only two molar excess of
cyclodextrin (L. Vaahtera and J. Parkkinen et al., unpublished
results), suggestive of improved bioavailability.
In view of the antitumor effects of curcumin on UC, the
accessibility of the bladder for local therapy, and the potential
synergistic effect of CDC and BCG, we hypothesized that
CDC may be a treatment modality for NMIBC. In this
preclinical study, we tested the antiproliferative effect of
CDC on various bladder cancer cell lines in vitro and the
efficacy of CDC, BCG, and a combination of CDC+BCG
as intravesical treatment for bladder cancer in a syngeneic
orthotopic bladder cancer model in rats.
2. Materials and Methods
2.1. Study Drugs. Cyclodextrin-curcumin (CDC) 12 mg/ml
was prepared by a pH shift method: In a 0.18 mol/L sodium
hydroxide solution, 112 g/L hydroxypropyl-𝛾-cyclodextrin
(Wacker Chemie, Munich Germany) and 15 g/L curcumin
(Sabinsa Corporation, East Windsor, NJ, USA) were dis-
solved and the pH was adjusted to 6.0 using hydrochloric
acid and citric acid. This method yields a concentrated
aqueous solution of curcumin (32 mmol/l) in the presence
of 2-fold molar excess of hydroxypropyl-𝛾-cyclodextrin. The
stock solution was sterile filtered and diluted to the proper
concentrations with serum-free RPMI-1640 medium (Invit-
rogen, Carlsbad, California, USA) for in vitro experiments or
with 0.9% NaCl for in vivo experiments. This CDC solution
meets the pharmaceutical requirements for intravascular
administration.
For the in vivo experiments, BCG-Medac (Medac GmbH,
Hamburg, Germany), RIVM strain 1173-P2, 2×108 – 3×109
colony forming units were used. It was resuspended in 0.9%
NaCl within 10 minutes before use.
2.2. In Vitro Experiment
2.2.1. Cell Lines and Conditions. Human UC cell lines RT4,
RT112, 253J, and T24 represent well-differentiated, moder-
ately differentiated (2x), and poorly differentiated phenotypes
ofUC, respectively.TheAY-27 ratUC cell line usedwas estab-
lished from a primary bladder tumor in FANFT (N-[4-(5-
nitro-2-furyl)-2-thiazolyl]formamide) fed Fischer F344 rats.
Cells were cultured as a monolayer in RPMI-1640 medium
with L-glutamine (Invitrogen, Carlsbad, California, USA),
supplemented with 10% fetal calf serum (Sigma-Aldrich,
St. Louis, Missouri, USA), 100 U/mL penicillin G, and 100
𝜇g/mL streptomycin (Invitrogen, Carlsbad, California, USA)
in a humidified 95% air/5% CO
2
atmosphere at 37∘C. The
medium was replaced twice a week. When confluent, cells
were split using standard trypsinisation procedures.
2.2.2. Cell Viability. Cells were seeded in 96-well plates at
1∗104 cells/well in 100𝜇L culture medium. After 24 hours,
the medium was replaced by 100𝜇L study drug. CDC was
dissolved in serum-free medium at 0.6125 to 640 𝜇mol/L.
The AY27 cells were treated for 0.5, 1, or 2 hours and the
human cell lines for 1 hour. After treatment, the cells were
rinsed three times using serum-free medium, then 100𝜇L
normal medium was added. At one or three days, a MTT cell
viability assaywas performed according to themanufacturers’
instruction (Sigma-Aldrich Co, St. Louis, Missouri, USA).
The experiments were performed in quadruplicate.
2.3. In Vivo Experiment
2.3.1. Animals. Study design and animal procedures were
approved by the Institutional Animal Care and Use Commit-
tee (IACUC), Committee for Animal Experiments (Radboud
University Nijmegen Medical Centre, The Netherlands), and
in compliance with Dutch and European regulations. Eighty
Fischer F344 rats were purchased (Charles River, L’Arbresle
Cedex, France) and were acclimatized for one week before
the experiment. The rats, weighing 170g ± 10g, were housed
in cages (Techniplast, Milan, Italy) with gold flake bedding
(SPPS, Frasne, France) and environmental enrichment, with
free access to standard chow and water. Daily, the rats were
weighed and monitored for wellbeing. The sample size of
20 rats per group was calculated with 𝛼=5%, power of 80%,
tumor development in 80% of the rats [20], and an estimated
therapeutic effect of 50%.
2.3.2. Tumor Implantation. The rats received tumor cells in
the bladder at day 0 as described by Xiao et al. [21]. Before
catheterization, enrofloxacin (Bayer, Leverkusen, Germany)
(5-10 mg/kg) was injected subcutaneously for antibacterial
prophylaxis. Experiments were performed under inhalation
anesthesia: Isoflurane 2-5% (induction), followed by Isoflu-
rane 2% and oxygen 1 L/min. The urethra was catheterized
with a 16-gauge plastic intravenous cannula (BD Biosystems,
Erembodegem-Aalst, Belgium) and drained. The bladder
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Figure 1: Relative cell survival of four human urothelial carcinoma cell lines and one rat urothelial carcinoma cell line (AY27) after 1 hour
of treatment with cyclodextrin-curcumin (CDC). Cell viability is relative to untreated cells. The MTT cell survival assay was performed 24
hours (a) and 72 hours (b) after treatment. Error bars represent standard error of the mean (SEM). Tests were performed in quadruplicate.
was preconditioned with a 15 sec instillation of 0.4 mL 0.1
M hydrochloride and neutralized by adding 0.4 mL 0.1 M
potassium hydroxide for 15 sec. The bladder was drained and
flushed 3 times with 0.8 mL 0.01 M PBS. AY27 cells were
harvested, counted, and resuspended in medium to reach
a concentration of 3∗106 cells/mL. Within 30 minutes after
harvesting, 0.5mL of the cell suspension was instilled in the
bladder and left indwelling for 1 hour. The rats were rotated
90∘ every 15 minutes to optimize bladder exposure. After 1
hour, the catheter was removed.
2.3.3. Study Design and Treatment. The rats were treated
intravesically three, seven, and ten days after tumor cell
implantation. First, the rats were anaesthetized as described
before. The urethra was catheterized, and the bladder was
emptied by gentle pressure on the abdomen. Group 1 was
treated with 0.5mL 300𝜇mol/L curcumin-cyclodextrin com-
plex dissolved in 0.9% NaCl. Group 2 was treated with 0.5mL
BCG (BCG-Medac (Medac GmbH, Hamburg, Germany),
RIVM strain 1173-P2, and 2×108 – 3×109 CFU). Group 3
received first an instillation with CDC for one hour and,
after rinsing three times with NaCl, an instillation for one
hour with 0,5 mL BCG. Group 4 received 0.5 mL 0.9% NaCl
intravesically as placebo. After treatment, the bladder was
emptied.
2.3.4. Tumor Evaluation. At day 14, the rats were sacri-
ficed using carbon dioxide inhalation. Internal organs were
inspected for abnormalities. The bladder was removed,
weighed, fixed in formalin 4% (Boom B.V., Meppel, The
Netherlands), laminated in 1-2mm slices, and embedded
in paraffin. Sections of 5𝜇m at two depths per lamella
were stained using haematoxylin and eosin. A specialized
uropathologist (C.H.K.) evaluated tumor stage according to
the TNM-classification and tumor grade according to the
2004 WHO/ISUP classification. The degree of inflammation
in mucosa and submucosa was quantified as no reaction,
mild, moderate, or severe inflammation.
3. Results
3.1. In Vitro. One hour of CDC treatment of UC cell lines
resulted in a dose-dependent antiproliferative effect (Fig-
ure 1). The 50% inhibitory concentration (IC-50) of CDC in
𝜇mol/L after one and three days of incubation was 15.9 and
17.6 for RT4, 41.3 and 23.5 for 253J, 15.1 and 28.9 for AY-27,
19.3 and 34.6 for T24, and 15.2 and 37.2 for RT112. Treatment
with 160𝜇mol/L CDC for 1 hour resulted in complete cell kill.
The antiproliferative effect was enhanced when treatment
was prolonged: when AY-27 cells were treated for 30, 60, and
120 minutes, the IC-50 of CDC decreased: 16.5 𝜇mol/L after
120 min treatment, 28.9 𝜇mol/L after 60 minutes, and 55.1
𝜇mol/L after 30 minutes (Figure 2).
3.2. In Vivo
3.2.1. Macroscopy. The rats received three instillations with
CDC, BCG, CDC+BCG, or NaCl. Two rats died during
the experiment. One rat (CDC+BCG group) died one day
after tumor cell instillation and was excluded from the
analysis.The other rat (NaCl group) died just after the second
instillation during anesthetic emergence. This rat had a pTa
tumor and was included for the pathologic stage evaluation.
At necropsy, no abnormalities were found on abdominal
organs in both rats and the bladders were intact.
The other 78 rats recovered well from four times
anesthesia and three instillations. There were no signs of
impaired wellbeing or infections. Two (tumor-positive) rats
(CDC+BCG and NaCl group) had hematuria but showed
no other signs of tumor related problems. At necropsy, no
abdominal abnormalities were found.
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Table 1: Pathological stage per treatment group. CDC: cyclodextrin-curcumin, BCG: Bacillus CalmetteGue´rin, NMIBC: non-muscle invasive
bladder cancer, and MIBC: muscle invasive bladder cancer.
Treatment group
Tumor free
pT0
N (%)
NMIBC
pTa, pT1
N (%)
MIBC
pT2, pT3
N (%)
Total
N (%)
(1) CDC 8 (40.0) 4 (20.0) 8 (40.0) 20 (100)
(2) BCG 5 (25.0) 2 (10.0) 13 (65.0) 20 (100)
(3) CDC+BCG 6 (31.6) 6 (31.6) 7 (36.8) 19 (100)
(4) NaCl (control) 3 (15.0) 5 (25.0) 12 (60.0) 20 (100)
Total 22 (27.8) 17 (21.5) 40 (50.6) 79 (100)
0,5 H incubation
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Figure 2: Relative cell survival of rat urothelial carcinoma cells
(AY27) after treatment with cyclodextrin-curcumin (CDC) for 30,
60, and 120 minutes. Cell viability relative to untreated cells. The
MTT cell survival assay was performed 72 hours after treatment.
Error bars represent standard error of the mean (SEM).
3.2.2. Pathology. The number of tumor-free rats was eight
(40%) in the group treated with CDC; five (25%) in the
group treatedwith BCG; six (36.6%) in the group treatedwith
CDC+BCG; and three (15%) for the NaCl group (Table 1).
The number of tumor-free rats was higher in the CDC and
CDC+BCGgroup compared to theNaCl-control, but this did
not reach statistical significance (Fischer’s Exact Test p=0.078
and 0.199, respectively). All tumors represented high-grade
UC. Tumor stages included pTa, pT1, pT2, and pT3 and
were not related to the treatment group (Kruskal Wallis test,
Chi2=3.95, p=0.267). Fourteen days after tumor induction,
the tumor progressed to a muscle invasive bladder tumor
in 50.6% of the rats. Half of the pT3 tumors were seen
in the NaCl group. Three of the four pT3 tumors in the
NaCl group showed macroscopically extravesical extension
(pT3b). Extravesical extension was not observed in the
treatment groups.
3.2.3. Inflammation. Nineteen rats (23.8%) showed no
signs of inflammation, 46 (57.5%) showed mild, and 15
(18.8%) showed moderate inflammation of the bladder.
Severe inflammation was absent. Bladder inflammation was
characterized by a granulomatous reaction with influx of
macrophages and polymorphonuclear lymphocytes. There
was no difference in the nature or degree of inflammation
between treatment and/or NaCl group(s).
4. Discussion
Curcumin, a food spice, is a nontoxic agent with antiprolif-
erative activity against urothelial carcinoma (UC) in vitro [5,
22, 23] and in vivo [7–10]. Because the bioavailability of cur-
cumin is hindered by its poor water solubility, cyclodextrin-
curcumin (CDC) complex was produced to improve its
solubility, stability, and bioavailability.
In this study, we show that CDC exerts a dose-dependent
antiproliferative effect on human and rat UC cell lines.
Moreover, intravesical treatment of CDC with and without
BCG in rats bearing bladder cancer resulted in a lower
number of tumor-positive rats compared to the NaCl-control
group although this did not reach statistical significance.
4.1. In Vitro. Five UC cell lines were treated with CDC
for 1 hour, to mimic the clinical situation of intravesical
instillation. The IC-50 varied and ranged from 15.1 to 41.3
𝜇mol/L, likely reflecting the different phenotypes of the
cell lines. The IC-50 are within the range of other in vitro
studies on curcumin treatment of urothelial cells (3.9-20.5
uM [5]) but also other malignant cell types (10.5-14.5 uM
in mammary, prostate, and ovarian carcinoma [24]). Longer
exposure to CDC resulted in more cell kill of AY-27; when
treatment times doubled, the IC-50 values decreased with
50%.This may have clinical implications because intravesical
treatment typically lasts one hour, but extended treatment
times depend on the patient’s ability to retain the instillation
longer.
The effects of CDC on a two-dimensional cell culture
cannot directly be compared to a three-dimensional model.
Differences in architecture and extracellular matrix alter the
efficacy of CDC [5]. Therefore, we conducted an in vivo
experiment.
4.2. In Vivo. To resemble the clinical situation as much
as possible with consecutive intravesical instillations, we
used the orthotopic bladder cancer model in F344 rats
with syngeneic AY-27 UC cells. Rats were treated with
an intravesical instillation three, seven, and ten days after
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tumor cell implantation and sacrificed on day 14. BCG and
a combination of CDC+BCG were included as treatment
modalities since BCG is standard treatment for NMIBC [2]
and curcumin may potentiate the efficacy of BCG [7].
We demonstrate that treatment with CDC and
CDC+BCG results in a lower percentage of tumors (60% and
68%, respectively) compared to NaCl-control (85%). This
difference was not statistically significant (p=0.078 and 0.199,
respectively), but we observed that the majority of high-stage
tumors were present in the NaCl and BCG-treated rats. In
this aggressive model, it is encouraging that we observed less
and lower-staged tumors in the CDC-treated groups.
Curcumin is under investigation as possible therapeutic
moiety for a variety of malignancies, including urological
tumors. Only few in vivo studies report intravesical treatment
with curcumin or CDC for a urological malignancy [8–10],
but not in combination with BCG. Leite et al. used an ortho-
topic mouse model with MB49 UC, treated twice weekly
with an intravesical instillation of curcumin [8]. They report
a significant reduction in tumor size for the treated mice,
compared to placebo, but no effect on number of tumors
or invasion depth. Another in vivo study, using the same
orthotopic bladder cancermousemodel, treated animals with
four intravesical treatments of curcumin [10]. They report a
positive effect on tumor necrosis in the curcumin treatment
rats, but no effect on tumor size or number. Opposed to these
studies, our experiment used tumor-free rats as the endpoint.
By using the cyclodextrin-curcumin complex, we aimed at
higher cellular uptake and improved efficacy because of
improved bioavailability [17, 19, 25] compared to unmodified
curcumin used in these studies.
Curcumin and BCG share pathways responsible for a
tumor selective antiproliferative effect by suppressing tran-
scription factors, like NF-𝜅B, responsible for proliferation,
invasion, and angiogenesis [7, 11–13], and by inducing apop-
tosis via TRAIL [7, 15]. In vitro and in vivo evidence indicate
additive effects of curcumin and BCG treatment for UC
[7]: Intratumorally administered BCG combined with oral
fed curcumin immediately after tumor grafting resulted in
a significant reduction in tumor volume compared to BCG
alone, curcumin alone, or placebo. Although this model is a
poor reflection of the clinical situation, it shows the possible
potentiating effect of curcumin [7]. Comparing this study
to our results is difficult, since the bioavailability of both
curcumin and BCG differs greatly after oral and intratumoral
administration, compared to intravesical instillation respec-
tively. Moreover, in our treatment schedule animals were
treated after tumor establishment, i.e., in a therapy setting,
whereas the other study was more of a protective setting. Our
experiment did not show an additional or synergistic effect of
the combination CDC+BCG over CDC alone (31.6% tumor-
free rats versus 40%, respectively). The number of tumor-
positive rats per group was too low to observe statistically
significant results between these groups. But interestingly, for
tumor-positive rats, the combination treatment resulted in a
slightly higher ratio of NMIBC/MIBC compared to the CDC
treatment: 6/7 versus 4/8. This indicates a positive treatment
effect compared toBCGalone (2/13) in the spectrumof tumor
development from NMIBC to MIBC.
Combination treatments of an immunomodulator with
a chemotherapeutic (like Mitomycin-C, Gemcitabine, Epiru-
bicin, etc.) or with another immunomodulator (Curcumin,
Interferon) have shown favorable results [7, 26]. Advantages
of combining agents may lie in a potentiating effect on uptake
or synergistic stimulation of apoptosis factors, as described
before. Future research will focus on the combining well-
known agents with new or established treatments.
The results of BCG treatment in our experiment are
mediocre. Xiao reports a lower percentage of tumor-bearing
rats (58%) after BCG treatment in the same AY27 model,
compared to us (75%) [27]. Two other in vivo experiments
show a comparable and more modest result of BCG with
64% and 75% tumor-positive mice after intravesical BCG
treatment [28, 29]. BCG treatment showed a limited antitu-
mor effect compared to clinical data. Possibly, the evaluation
time was too short as the induction of the effector T-cells
responsible for the antitumor effect requires a number of
days. Moreover, the magnitude of T-cell response increases
synergistically with each treatment and may need weeks to
fully exert its effect [30]. Longer follow-up after treatment
may be preferable, but because of the aggressiveness of the
model, we chose to sacrifice the animals after two weeks.
Xiao et al. used a different study design; theymonitored F344
rats with AY-27 tumors for 90 days and euthanized animals
when clinical signs of tumor progression became apparent
[27]. Survival studies might have shown differences between
treatment groups, but considering the advanced tumors in
many animals, this seems unlikely for our experiments.
Our results indicate that the model used may be too
aggressive to evaluate investigational agents that need a
certain amount of time to fully exert their antitumor effect.
The AY-27 orthotopic bladder cancer rat model used was
first described by Xiao et al. Muscle invasive tumors are to
be expected, since the urothelium first needs to be damaged
before tumor cells can attach and grow [21]. The model
appears to be more aggressive than originally described.
Hendicksen et al. assessed the tumor growth over time in
the AY27 model and found that, after 6 days, already 40%
of the rats progressed to MIBC (pT2, pT3) [20]. Considering
that both curcumin and BCG work as immunomodulators,
rapid tumor development may overshadow the antitumor
effect.
Due to limited penetration depth, intracellular concen-
tration of the drug is lower at the base of larger tumors, con-
tributing to possible lower treatment effects. In future in vivo
studies, ideally the tumor load before start of the treatment
should be limited to assure tumor cell-drug contact.
5. Conclusions
Being a nontoxic agent, curcumin possesses a variety of
propertiesmaking it a potential cancer treatment or enhancer
of existing treatments. The cyclodextrin-complexed formu-
lated curcumin with improved bioavailability showed a dose-
dependent antiproliferative effect on the rat AY-27 and
various human UC cell lines in vitro. Intravesical instillation
of CDC for the treatment of bladder cancer with and
without BCG demonstrated a promising antitumor response.
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Extrapolating to the clinical situation, (adjuvant) treatment
with CDC deserves a successive study.
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